Efficacy, safety and tolerability of orlistat, a lipase inhibitor, in the treatment of adolescent weight excess
| Autor: | Roberto Bogarin, Jean-Pierre Chanoine |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
business.industry General Medicine Adolescent Obesity medicine.disease Obesity Orlistat Endocrinology Tolerability Weight loss Internal medicine Lipase inhibitors medicine Pharmacology (medical) Behavioral interventions medicine.symptom business Body mass index medicine.drug |
| Zdroj: | Therapy. 6:23-30 |
| ISSN: | 1744-831X 1475-0708 |
| DOI: | 10.2217/14750708.6.1.23 |
| Popis: | The treatment of childhood and adolescent obesity is difficult and the outcome of behavioral interventions remains unsatisfactory. Several pharmacological approaches, used in conjunction with comprehensive behavioral interventions designed to improve diet and decrease inactivity have been developed and extensively studied, mainly in adults. Orlistat is a lipase inhibitor that reduces dietary fat absorption by a third. It is the only pharmacological agent approved in the pediatric age group for the treatment of obesity. The goal of this article is to review the efficacy and safety of orlistat in adolescents, with emphasis on its effects on weight and body mass index, body composition and liposoluble vitamins during growth. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|